Literature DB >> 18220719

Antioxidant therapy for prevention of inflammation, ischemic reperfusion injuries and allograft rejection.

Anlun Ma1, Shijie Qi, Huifang Chen.   

Abstract

Oxidative stress results from an imbalance, an excess of oxidants, depletion of antioxidants or failure to repair oxidative damage induced by reactive oxygen species. A vast amount of evidence implicates oxygen-derived free radicals and high-energy oxidants as mediators in many pathological conditions of inflammation, shock, and organ responses to ischemia/reperfusion, which arise during a number of clinical surgical interventions, including transplant graft rejection and coronary bypass surgery, and in such diseases as, diabetes, atherosclerosis, hypertension, organ ischemia/reperfusion, cardiovascular inflammation, cardiac/brain infarction, cancer, pulmonary emphysema and autoimmune diseases. To eliminate or attenuate oxidative stress, antioxidant therapies have been developed and may be of great help to these patients. This review describes recent developments in the field of oxidative stress research and antioxidant function, summarizes new pharmacological strategies that are ongoing in antioxidant therapy with small molecules, free radical-scavenging enzymes, superoxide dismutases, catalase mimetics, flavonoids, vitamins and poly polymerase inhibitors, and presents experimental and clinical evidence of the role of antioxidants in diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18220719     DOI: 10.2174/187152508783329966

Source DB:  PubMed          Journal:  Cardiovasc Hematol Agents Med Chem        ISSN: 1871-5257


  9 in total

1.  Boric acid: a potential chemoprotective agent against aflatoxin b(1) toxicity in human blood.

Authors:  Hasan Turkez; Fatime Geyikoglu
Journal:  Cytotechnology       Date:  2010-04-30       Impact factor: 2.058

2.  Optimization of ultrasound contrast agents with computational models to improve selection of ligands and binding strength.

Authors:  Timothy M Maul; Drew D Dudgeon; Michael T Beste; Daniel A Hammer; John S Lazo; Flordeliza S Villanueva; William R Wagner
Journal:  Biotechnol Bioeng       Date:  2010-12-01       Impact factor: 4.530

3.  Anti-inflammatory treatment strategies for ischemia/reperfusion injury in transplantation.

Authors:  Jens Lutz; Klaus Thürmel; Uwe Heemann
Journal:  J Inflamm (Lond)       Date:  2010-05-28       Impact factor: 4.981

Review 4.  Forever young: mechanisms of natural anoxia tolerance and potential links to longevity.

Authors:  Anastasia Krivoruchko; Kenneth B Storey
Journal:  Oxid Med Cell Longev       Date:  2010 May-Jun       Impact factor: 6.543

5.  Diosgenin attenuates inflammatory response induced by myocardial reperfusion injury: role of mitochondrial ATP-sensitive potassium channels.

Authors:  Hadi Ebrahimi; Reza Badalzadeh; Mustafa Mohammadi; Bahman Yousefi
Journal:  J Physiol Biochem       Date:  2014-02-18       Impact factor: 4.158

Review 6.  Microencapsulated drug delivery: a new approach to pro-inflammatory cytokine inhibition.

Authors:  Carl W Oettinger; Martin J D'Souza
Journal:  J Microencapsul       Date:  2012-02-21       Impact factor: 3.142

7.  Comparative effects of triflusal, S-adenosylmethionine, and dextromethorphan over intestinal ischemia/reperfusion injury.

Authors:  Carlos R Cámara-Lemarroy; Francisco J Guzmán-de la Garza; Paula Cordero-Pérez; Gabriela Alarcón-Galván; Liliana Torres-Gonzalez; Linda E Muñoz-Espinosa; Nancy E Fernández-Garza
Journal:  ScientificWorldJournal       Date:  2011-10-24

8.  Tannin extracted from Sumac inhibits vascular smooth muscle cell migration.

Authors:  Hanieh Zargham; Ramin Zargham
Journal:  Mcgill J Med       Date:  2008-07

9.  The poly(adenosine diphosphate-ribose) polymerase inhibitor PJ34 reduces pulmonary ischemia-reperfusion injury in rats.

Authors:  Go Hatachi; Tomoshi Tsuchiya; Takuro Miyazaki; Keitaro Matsumoto; Naoya Yamasaki; Naoyuki Okita; Atsushi Nanashima; Yoshikazu Higami; Takeshi Nagayasu
Journal:  Transplantation       Date:  2014-09-27       Impact factor: 4.939

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.